The Innovative Medicines Initiative was created in 2007 to speed up drug development and give European pharma a competitive edge. Four years on, IMI divides opinion, as Tania Rabesandratana reports.
“The United States clearly envies the Innovative Medicines Initiative,” says Michel Goldman, the programme’s chief executive in Brussels. “They are aware that Europe has taken the lead.”
A US Jobs Council report published on 10 October mentioned IMI as an exemplary scheme to attract international drug companies. In the report, President Barack Obama’s competitiveness advisers said: “Europe, China and India continue to entice companies to take their medical R&D enterprises abroad, putting at risk our ability to keep private investment and jobs here at home.”
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.